Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naim Alkhouri

Showing results (261-270 of 306) with videos related to

Pageof 31
Sort By:
Journal of Hepatology|April 19, 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialNaim Alkhouri, Robert Herring, Heidi Kabler, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Journal of Hepatology|March 22, 2021
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohortStephen A Harrison, Samer Gawrieh, Katharine Roberts, et al.
Metabolism: Clinical and Experimental|December 4, 2020
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progressionNisreen Nimer, Ibrahim Choucair, Zeneng Wang, et al.
Hepatology Communications|May 9, 2022
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018Emily Truong, Yee Hui Yeo, Galen Cook-Wiens, et al.
The Lancet. Gastroenterology & Hepatology|August 8, 2021
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statementMohammed Eslam, Naim Alkhouri, Pietro Vajro, et al.
Nature Medicine|January 27, 2025
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitisAli Aminian, Abdullah Aljabri, Sarah Wang, et al.
Gastroenterology|December 9, 2019
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionNaga Chalasani, Manal F Abdelmalek, Guadalupe Garcia-Tsao, et al.
JAMA|November 11, 2021
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisAli Aminian, Abbas Al-Kurd, Rickesha Wilson, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
Pageof 31

Showing results (261-270 of 306) with videos related to

Sort By:
Pageof 31
Journal of Hepatology|April 19, 2022
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trialNaim Alkhouri, Robert Herring, Heidi Kabler, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Journal of Hepatology|March 22, 2021
Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohortStephen A Harrison, Samer Gawrieh, Katharine Roberts, et al.
Metabolism: Clinical and Experimental|December 4, 2020
Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progressionNisreen Nimer, Ibrahim Choucair, Zeneng Wang, et al.
Hepatology Communications|May 9, 2022
Nonalcoholic fatty liver disease prevalence and severity in Asian Americans from the national health and nutrition examination surveys 2017-2018Emily Truong, Yee Hui Yeo, Galen Cook-Wiens, et al.
The Lancet. Gastroenterology & Hepatology|August 8, 2021
Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statementMohammed Eslam, Naim Alkhouri, Pietro Vajro, et al.
Nature Medicine|January 27, 2025
Long-term liver outcomes after metabolic surgery in compensated cirrhosis due to metabolic dysfunction-associated steatohepatitisAli Aminian, Abdullah Aljabri, Sarah Wang, et al.
Gastroenterology|December 9, 2019
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal HypertensionNaga Chalasani, Manal F Abdelmalek, Guadalupe Garcia-Tsao, et al.
JAMA|November 11, 2021
Association of Bariatric Surgery With Major Adverse Liver and Cardiovascular Outcomes in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisAli Aminian, Abbas Al-Kurd, Rickesha Wilson, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
Pageof 31